The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has introduced a groundbreaking medication for patients with Pulmonary Arterial Hypertension, making Abu Dhabi the first in the region to offer such medication.

This advancement represents a significant step forward in enhancing patient care and healthcare outcomes for individuals with this condition.

Administered via subcutaneous injection every three weeks in specified doses, WINREVAIR can be self-administered by patients or caregivers under medical supervision.